Kawashima Hidenori, Kimura Yasunori
Shirahama Hamayu Hospital, Shirahama, Wakayama 649-2211, Japan.
J Kidney Cancer VHL. 2015 Apr 4;2(2):55-63. doi: 10.15586/jkcvhl.2015.24. eCollection 2015.
Metastatic lesions of renal cell carcinoma (RCC) occasionally regress spontaneously after surgical removal of the primary tumor. Although this is an exceptionally rare occurrence, RCC has thus been postulated to be immunogenic. Immunotherapies, including cytokine therapy, peptide-based vaccines, and immune checkpoint inhibitors have therefore been used to treat patients with advanced, metastatic RCC. We review the history, trends, and recent progress in immunotherapy for advanced RCC and discuss future perspectives, with consideration of our experimental work on galectin 9 and PINCH as promising specific immunotherapy targets.
肾细胞癌（RCC）的转移病灶在手术切除原发肿瘤后偶尔会自发消退。尽管这种情况极为罕见，但由此推测RCC具有免疫原性。因此，包括细胞因子疗法、基于肽的疫苗和免疫检查点抑制剂在内的免疫疗法已被用于治疗晚期转移性RCC患者。我们回顾了晚期RCC免疫治疗的历史、趋势和最新进展，并讨论了未来前景，同时考虑了我们关于半乳糖凝集素9和PINCH作为有前景的特异性免疫治疗靶点的实验工作。
